February 2024
Molecular mechanism of action in leukemic cells uncovered

April 2022
EP, US, JP, CA pending

August 2021
LeucoTox starts testing treatment efficacy in primary human AML showing efficacy in leukemic stem cells.

November 2020
EPO Patent Publication

August 2020
LeucoTox performed first patient-derived xenograft experiments with substantial treatment efficacy.

October 2020
Preclinical models show efficacy of LeucoTox in myeloid leukemia in vivo.

May 2019
LeucoTox submitted patent application at the European Patent Office.